-
Bio-Thera Solutions and SteinCares Ink Licensing Deal for LatAm Biosimilar Distribution
•
Bio-Thera Solutions (SHA: 688177), a Chinese biopharmaceutical company, has entered into a licensing agreement with SteinCares, a Costa Rican healthcare provider. Under the terms of the deal, SteinCares will obtain exclusive rights to distribute and market two of Bio-Thera’s biosimilars across Brazil and the Latin America (LatAm) region. The financial…
-
C&Y Pharmaceutical Teams Up with GigaCeuticals to Form AI-Driven Drug Development JV
•
Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254), a Chinese pharmaceutical company, is venturing into a joint venture (JV) with Beijing-based AI-driven drug developer GigaCeuticals. The new JV, valued at RMB 120 million (USD 16.7 million), aims to collaborate on the research and development, industrialization, and commercialization of innovative drugs…
-
GSK’s Jemperli Shows Survival Benefits in Phase III Endometrial Cancer Study
•
GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has presented early results from a Phase III study for its PD-1-blocking antibody Jemperli (dostarlimab) in the treatment of primary advanced or recurrent endometrial cancer. The placebo-controlled trial aims to expand the current indication for frontline mismatch repair deficient (dMMR)/microsatellite instability-high…
-
Akeso Biopharma Reports Record Revenue and First Profit, Driven by Innovative Drugs
•
Akeso Biopharma (HKG: 9926) has announced its financial results for 2023, reporting a record revenue of RMB 4.526 billion (USD 629 million), marking a staggering 440% year-on-year increase. The company, based in China, posted its first annual profit with net earnings reaching RMB 1.942 billion (USD 269.7 million). Innovative drugs…
-
uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors
•
uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU) Wisdom Lake Academy of Pharmacy to develop innovative chimeric antigen receptor natural killer (CAR-NK) cell therapies. The collaboration aims to advance the field of immunotherapy by creating two distinct types of CAR-NK cell treatments. The…
-
Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia
•
Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license agreement with Sosei Group Corporation (TSE: 4565), a Japanese firm. This strategic partnership aims to develop and commercialize Sosei Heptares’ portfolio of first-in-class GPR52 agonists, targeting a novel G protein-coupled receptor (GPCR) to address the…
-
BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma
•
BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has granted approval for its programmed death-1 (PD-1) inhibitor, tislelizumab, as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC). The approval is for patients who have been previously treated…
-
Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080
•
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has announced a licensing agreement with domestic firm Biotheus. Under the terms of the agreement, Hansoh will secure exclusive global rights to develop, manufacture, and commercialize Biotheus’s bispecific antibody (BsAb) HS-20117/PM1080, along with sub-license rights. The…
